NCT06846905 Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.
| NCT ID | NCT06846905 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Toulouse |
| Condition | Multiple Myeloma in Relapse |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-01-20 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2025-01-20 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multiple myeloma is the second most common haematological cancer. Recent innovations have made it possible for relapsed/refractory patients to benefit from the innovative immunotherapy of bispecific antibodies. These antibodies stimulate the immune system to attack tumour cells. The treatment involves an escalating dose of three subcutaneous injections every 2 to 4 days for a total of about 10 days, followed by a weekly treatment phase. The University Hospital of Toulouse was the first centre in France to offer outpatient dose escalation for this innovative treatment. This form of treatment depends on clinical and logistical feasibility. Where appropriate, patients are treated in a conventional unit. An analysis carried out at Toulouse University Hospital suggests a response to treatment, with no increased risk of complications in the outpatient setting. Patients' quality of life may also be unaffected. In addition, given the increasing demand for care in a context of finite resources, the economic evaluation of healthcare initiatives is becoming essential if we are to maintain a high-quality healthcare system that is accessible to all.
Eligibility Criteria
Inclusion Criteria: * Relapsed and/or refractory multiple myeloma * Treated with teclistamab, elranatamab ou talquetamab * More than 18 years old * Having received the information from the study and not having objected to participate * Day hospital care in case of clinical feasibility (good general condition, no rapid progression or major tumor burden, no current infection) and logistics (accommodated less than 30 minutes from the IUCT Oncopole for 48 hours after each dose escalation) or in conventional hospitalization at the IUCT Oncopole Exclusion Criteria: * Illiterate subjects or those with a language barrier
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06846905 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma in Relapse. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06846905 currently recruiting?
Yes, NCT06846905 is actively recruiting participants. Contact the research team at perrot.aurore@iuct-oncopole.fr for enrollment information.
Where is the NCT06846905 trial being conducted?
This trial is being conducted at Toulouse, France.
Who is sponsoring the NCT06846905 clinical trial?
NCT06846905 is sponsored by University Hospital, Toulouse. The trial plans to enroll 40 participants.